Dementia Support Line
LACI-Cog-1: a study testing two medicines in people with vascular dementia
Status
Contact
The Clinical Trial Finder is for information only. To join a clinical trial you must meet the eligibility criteria set by the study and the research team will discuss this with you.
Trial description
What is the aim of the study?
Memory and thinking problems (sometimes called cognitive impairment) can be caused by damage to the small blood vessels of the brain. This is called small vessel disease. It is the commonest cause of vascular cognitive impairment and vascular dementia.
At the moment there is no specific treatment for the thinking and memory problems caused by small vessel disease.
Researchers have been studying two medicines, cilostazol and isosorbide mononitrate, which are already used to treat other health conditions. Previous studies suggest that these medicines may help protect the brain's small blood vessels from further damage. They have also been shown to be safe and well tolerated by people who have had a stroke caused by small vessel disease.
The aim of the LACI-Cog-1 trial is to research if these drugs could also help people with memory or thinking problems due to small vessel disease.
What will participants be asked to do during the study?
People in the study will be put into their treatment groups by chance, like flipping a coin. There are 4 treatment options that a person could be given:
- Isosorbide mononitrate
- Cilostazol
- Both medications together
- Neither medication (usual care only)
The study treatment will be given as a tablet.
During the study, participants will:
- Have brain scans called magnetic resonance imaging (MRI) scans. These scans take detailed pictures of the brain to help doctors check brain health and safety
- Complete tests that look at memory, thinking, and emotional wellbeing
If participants would like more details about the tests, procedures, or number of visits, the study team can provide full information.
Eligibility criteria
Who can take part
- People with mild cognitive impairment or mild dementia.
- If you have a brain scan showing moderate-to-severe small vessel disease, which is thought to be the main cause of the cognitive problems.
- If you have capacity to provide written consent themselves.
- You must have a study partner (a close friend or family member who has regular contact with you and can provide information at study visits).
Who cannot take part
- If you are unable to manage medications themselves and does not have sufficient family/carer support to help them take the trial medications.
- If you area woman of childbearing potential.
- If you have severe renal (kidney) or moderate-to-severe liver failure.
Clinical trial team
Age range
Recruitment start
Disease type
Mechanism of action
Trial locations
Eligibility criteria
Who can take part
- People with mild cognitive impairment or mild dementia.
- If you have a brain scan showing moderate-to-severe small vessel disease, which is thought to be the main cause of the cognitive problems.
- If you have capacity to provide written consent themselves.
- You must have a study partner (a close friend or family member who has regular contact with you and can provide information at study visits).
Who cannot take part
- If you are unable to manage medications themselves and does not have sufficient family/carer support to help them take the trial medications.
- If you area woman of childbearing potential.
- If you have severe renal (kidney) or moderate-to-severe liver failure.